Literature DB >> 19732738

Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma.

Evelien Heylen1, Sebastiaan Van Goethem, Johan Willemse, Thomas Olsson, Koen Augustyns, Dirk Hendriks.   

Abstract

To date, several assays for procarboxypeptidase U (proCPU) determination exist, all having their own inherent disadvantages and advantages. A drawback of activity-based assays is the interference of the constitutively active carboxypeptidase N (CPN) in plasma. Recent screening of Bz-Xaa-Arg peptides with modified aromatic amino acids at the P1 position revealed a selective CPU substrate, N-benzoyl-ortho-cyano-phenylalanyl-arginine (Bz-o-cyano-Phe-Arg), which will allow straightforward determination of proCPU in plasma. Our assay shows an excellent linearity in the concentration range of 20-2600 U/L, with within- and between-run precision values of 2.7% and 4.6%, respectively. A good correlation with our high-performance liquid chromatography (HPLC)-assisted proCPU activity assay using hippuryl-l-arginine (HipArg) as substrate was found. Besides the major improvement regarding the selectivity, the assay is much easier to perform and far less time-consuming compared with the proCPU activity assay using HipArg as substrate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732738     DOI: 10.1016/j.ab.2009.08.037

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  4 in total

1.  Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis.

Authors:  Paul Y Kim; Paula Y G Kim; Fletcher B Taylor; Michael E Nesheim
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

Review 2.  Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

Authors:  Karen Claesen; Joachim C Mertens; Dorien Leenaerts; Dirk Hendriks
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

3.  A Case-Control Study of the Dose-Response Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Acute Myocardial Infarction.

Authors:  Mengnan Zhao; Dan Zhao; Yuning Li; Xiaonan Wang; Boyu Yi; Bo Zhou
Journal:  Front Cardiovasc Med       Date:  2022-02-28

4.  Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.

Authors:  Karen Claesen; Yani Sim; An Bracke; Michelle De Bruyn; Emilie De Hert; Gwendolyn Vliegen; An Hotterbeekx; Alexandra Vujkovic; Lida van Petersen; Fien H R De Winter; Isabel Brosius; Caroline Theunissen; Sabrina van Ierssel; Maartje van Frankenhuijsen; Erika Vlieghe; Koen Vercauteren; Samir Kumar-Singh; Ingrid De Meester; Dirk Hendriks
Journal:  J Clin Med       Date:  2022-03-09       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.